Janux Therapeutics, Inc. (JANX)
Develops cancer immunotherapies that activate the body's T cells to attack tumors.
$14.81-0.05%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-37.1%
The outlook
JANX trades near its 52-week low, with the price sitting well below its moving averages in a mixed trend. Analyst sentiment is bearish overall, though the average price target sits roughly 151% above the current price, suggesting a wide gap between current valuation and analyst expectations. Coverage leans cautious relative to the stock's recent performance and positioning in its range.
What’s behind the score
Price trendMixed vs its moving averages
52-week range12% of the way from its 52-week low to high
Price targetAvg target +151% vs current price
Analyst price target
~12-month · 16 analysts$37.19average target+151.0% vs now
Now $14.81
Low $14.00High $72.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$903.4M
52-wk high
$35.34
52-wk low
$12.12
50-day avg
$14.80
200-day avg
$17.05
Trailing P/E
—